Massive european study probes pancreatic cancer risk in diabetes drug exenatide

NCT ID NCT05663515

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times

Summary

This study is checking if people with type 2 diabetes who take the drug exenatide have a higher chance of getting pancreatic cancer compared to those taking other diabetes medicines. Researchers will look at health records from over 24,000 adults in seven European countries. The goal is to better understand the long-term safety of exenatide.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Copenhagen, Denmark
Research Site
RECRUITING

Helsinki, Finland
Research Site
RECRUITING

Paris, France
Research Site
RECRUITING

Bergen, Norway
Research Site
RECRUITING

Barcelona, Spain
Research Site
RECRUITING

Vänersborg, Sweden
Research Site
RECRUITING

Edinburgh, United Kingdom
Research Site
RECRUITING

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

PANCREATIC CANCER